Total Funding
93
92
Total FundingSeries A raised
Growth Score
18 pts
Heat Score
57 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
9796
ALERCELL is an AI-Powered Molecular Diagnostic company specialized in early detection of Leukemia and Lung Cancer.
- Frederic Scheer: CEO & CSO
- Alexandre Scheer, MD: CEO & Chief Scientific Officer
About the Company
Alercell Inc. is a precision oncology company developing AI-powered epigenetic diagnostic platforms for the early detection of hematologic malignancies. The company's proprietary LENA Platform™ analyzes DNA methylation patterns to detect pre-leukemic signatures up to 41 months before clinical symptom onset, validated across more than 199,000
electronic medical records. Core technologies include the LENA Code™, LENA Score™, Deep Leukemic Cloud Platform™, and Alercell Epigenetic Clock™. Alercell is headquartered in Bozeman, Montana and is currently raising a Series A financing round to advance clinical validation and regulatory strategy.
